Healthcare [ 7/13 ] | Medical Instruments & Supplies [ 131/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 23 | -0.78 Increased by +1.27% | -0.58 Decreased by -34.48% |
| Aug 3, 23 | -0.92 Decreased by -8.24% | -0.67 Decreased by -37.31% |
| May 3, 23 | -0.88 Decreased by -2.33% | -0.73 Decreased by -20.55% |
| Feb 28, 23 | -0.95 Decreased by -48.44% | -0.58 Decreased by -63.79% |
| Nov 7, 22 | -0.79 Decreased by -14.49% | -0.51 Decreased by -54.9% |
| Aug 4, 22 | -0.85 Decreased by -41.67% | -0.68 Decreased by -25% |
| May 10, 22 | -0.86 Decreased by -38.71% | -0.56 Decreased by -53.57% |
| Mar 1, 22 | -0.64 Decreased by -20.75% | -0.59 Decreased by -8.47% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 48.09 M Increased by +63.2% | -37.41 M Decreased by -1.97% | Decreased by -77.8% Increased by +37.52% |
| Jun 30, 23 | 44.16 M Increased by +37.05% | -43.67 M Decreased by -11.29% | Decreased by -98.89% Increased by +18.8% |
| Mar 31, 23 | 35.8 M Increased by +15.2% | -41.24 M Decreased by -4.4% | Decreased by -115.17% Increased by +9.38% |
| Dec 31, 22 | 34.42 M Decreased by -18.92% | -44.11 M Decreased by -50.76% | Decreased by -128.16% Decreased by -85.94% |
| Sep 30, 22 | 29.47 M Decreased by -20.68% | -36.69 M Decreased by -17.37% | Decreased by -124.52% Decreased by -47.97% |
| Jun 30, 22 | 32.22 M Decreased by -4.85% | -39.24 M Decreased by -45.22% | Decreased by -121.79% Decreased by -52.63% |
| Mar 31, 22 | 31.08 M Decreased by -1.7% | -39.5 M Decreased by -42.54% | Decreased by -127.09% Decreased by -45% |
| Dec 31, 21 | 42.45 M Increased by +17.08% | -29.26 M Decreased by -27.2% | Decreased by -68.92% Decreased by -8.64% |
NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bank